Last reviewed 2026-04-20 · How we verify

Maleic acid

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Headache
• Arthralgia
• Somnolence
• Weight increased
• Dizziness
• Nasopharyngitis
• Fatigue
• Increased appetite
• Nausea
• Influenza
• Abdominal distension
• Insomnia

Key clinical trials

• Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) (PHASE2)
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
• Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
• Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (PHASE1)
• Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene (PHASE1)
• Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (PHASE1, PHASE2)
• Avatrombopag vs. Placebo for CIT in GI Malignancies (PHASE2)
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Maleic acid CI brief — competitive landscape report
• Maleic acid updates RSS · CI watch RSS
• Dow University of Health Sciences portfolio CI